NCT04088890 - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

November 7, 2024

Study Completion Date

March 7, 2025

Conditions

B-ALLB-cell Non Hodgkin LymphomaDLBCLFollicular Lymphoma Grade 3B

Interventions

DRUG

Fludarabine

Fludarabine 30 mg/m2

DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2

DRUG

CD22 CAR

Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D

Trial Locations (1)

94304

Stanford Medical Center, Stanford

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

American Society of Hematology

OTHER

lead

Stanford University

OTHER